{"id":22733,"date":"2022-03-31T14:14:10","date_gmt":"2022-03-31T13:14:10","guid":{"rendered":"https:\/\/ppr-antibioresistance.inserm.fr\/?p=22733"},"modified":"2022-03-31T14:14:12","modified_gmt":"2022-03-31T13:14:12","slug":"global-genomic-surveillance-strategy-for-pathogens-with-pandemic-and-epidemic-potential-2022-2032","status":"publish","type":"post","link":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/bilans-rapports-et-recommandations\/global-genomic-surveillance-strategy-for-pathogens-with-pandemic-and-epidemic-potential-2022-2032\/","title":{"rendered":"Global genomic surveillance strategy for pathogens with pandemic and epidemic potential, 2022\u20132032"},"content":{"rendered":"\n

Artcile published on the World Health Organization website<\/a> on March 28, 2022<\/p>\n\n\n\n

The Strategy provides a high-level unifying framework to leverage existing capacities, address barriers and strengthen the use of genomic surveillance in the detection, monitoring and response to public health threats. Genomic surveillance is part of the broader surveillance and laboratory system, and its implementation should reinforce end-to-end capacities including sample collection, diagnostics, data sharing and analysis. <\/p>\n\n\n\n

The strategy aims to facilitate the connectivity between different disease control programs and surveillance networks. This interoperability will strengthen the cross-cutting essential public health laboratory functions underpinning genomics holistically. The strategy articulates the overarching goal, objectives and strategic actions needed. <\/p>\n\n\n\n

These are dependent on commitments from countries, partners and WHO for their implementation.<\/p>\n\n\n\n

Download report<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Artcile published on the World Health Organization website on March 28, 2022 The Strategy provides a high-level unifying framework to leverage existing capacities, address barriers and strengthen the use of genomic surveillance in the detection, monitoring and response to public health threats. Genomic surveillance is part of the broader surveillance and laboratory system, and its […]<\/p>\n","protected":false},"author":139,"featured_media":22741,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_links_to":"","_links_to_target":""},"categories":[31,37],"tags":[],"acf":[],"yoast_head":"\nGlobal genomic surveillance strategy for pathogens with pandemic and epidemic potential, 2022\u20132032 - French\u00a0National ANTIBIOTIC RESISTANCE Portal<\/title>\n<meta name=\"description\" content=\"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l'Antibior\u00e9sistance en France et \u00e0 l'international.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/bilans-rapports-et-recommandations\/global-genomic-surveillance-strategy-for-pathogens-with-pandemic-and-epidemic-potential-2022-2032\/\" \/>\n<meta property=\"og:locale\" content=\"en_GB\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Global genomic surveillance strategy for pathogens with pandemic and epidemic potential, 2022\u20132032 - French\u00a0National ANTIBIOTIC RESISTANCE Portal\" \/>\n<meta property=\"og:description\" content=\"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l'Antibior\u00e9sistance en France et \u00e0 l'international.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/bilans-rapports-et-recommandations\/global-genomic-surveillance-strategy-for-pathogens-with-pandemic-and-epidemic-potential-2022-2032\/\" \/>\n<meta property=\"og:site_name\" content=\"French\u00a0National ANTIBIOTIC RESISTANCE Portal\" \/>\n<meta property=\"article:published_time\" content=\"2022-03-31T13:14:10+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2022-03-31T13:14:12+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2022\/03\/ADN.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"217\" \/>\n\t<meta property=\"og:image:height\" content=\"299\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"\u00c9milie Noguez\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"\u00c9milie Noguez\" \/>\n\t<meta name=\"twitter:label2\" content=\"Estimated reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"NewsArticle\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/bilans-rapports-et-recommandations\/global-genomic-surveillance-strategy-for-pathogens-with-pandemic-and-epidemic-potential-2022-2032\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/bilans-rapports-et-recommandations\/global-genomic-surveillance-strategy-for-pathogens-with-pandemic-and-epidemic-potential-2022-2032\/\"},\"author\":{\"name\":\"\u00c9milie Noguez\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#\/schema\/person\/6ae79ca06cbeaec66ef5e976b54606b3\"},\"headline\":\"Global genomic surveillance strategy for pathogens with pandemic and epidemic potential, 2022\u20132032\",\"datePublished\":\"2022-03-31T13:14:10+00:00\",\"dateModified\":\"2022-03-31T13:14:12+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/bilans-rapports-et-recommandations\/global-genomic-surveillance-strategy-for-pathogens-with-pandemic-and-epidemic-potential-2022-2032\/\"},\"wordCount\":132,\"publisher\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#organization\"},\"image\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/bilans-rapports-et-recommandations\/global-genomic-surveillance-strategy-for-pathogens-with-pandemic-and-epidemic-potential-2022-2032\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2022\/03\/ADN.jpg\",\"articleSection\":[\"Actualit\u00e9s\",\"Bilans, rapports et recommandations\"],\"inLanguage\":\"en-GB\"},{\"@type\":[\"WebPage\",\"ItemPage\"],\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/bilans-rapports-et-recommandations\/global-genomic-surveillance-strategy-for-pathogens-with-pandemic-and-epidemic-potential-2022-2032\/\",\"url\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/bilans-rapports-et-recommandations\/global-genomic-surveillance-strategy-for-pathogens-with-pandemic-and-epidemic-potential-2022-2032\/\",\"name\":\"Global genomic surveillance strategy for pathogens with pandemic and epidemic potential, 2022\u20132032 - French\u00a0National ANTIBIOTIC RESISTANCE Portal\",\"isPartOf\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/bilans-rapports-et-recommandations\/global-genomic-surveillance-strategy-for-pathogens-with-pandemic-and-epidemic-potential-2022-2032\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/bilans-rapports-et-recommandations\/global-genomic-surveillance-strategy-for-pathogens-with-pandemic-and-epidemic-potential-2022-2032\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2022\/03\/ADN.jpg\",\"datePublished\":\"2022-03-31T13:14:10+00:00\",\"dateModified\":\"2022-03-31T13:14:12+00:00\",\"description\":\"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l'Antibior\u00e9sistance en France et \u00e0 l'international.\",\"breadcrumb\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/bilans-rapports-et-recommandations\/global-genomic-surveillance-strategy-for-pathogens-with-pandemic-and-epidemic-potential-2022-2032\/#breadcrumb\"},\"inLanguage\":\"en-GB\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/bilans-rapports-et-recommandations\/global-genomic-surveillance-strategy-for-pathogens-with-pandemic-and-epidemic-potential-2022-2032\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-GB\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/bilans-rapports-et-recommandations\/global-genomic-surveillance-strategy-for-pathogens-with-pandemic-and-epidemic-potential-2022-2032\/#primaryimage\",\"url\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2022\/03\/ADN.jpg\",\"contentUrl\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2022\/03\/ADN.jpg\",\"width\":217,\"height\":299,\"caption\":\"Cr\u00e9dit : Pixabay\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/bilans-rapports-et-recommandations\/global-genomic-surveillance-strategy-for-pathogens-with-pandemic-and-epidemic-potential-2022-2032\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Practical info & communications\",\"item\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/info-communication\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Reviews, reports and recommendations\",\"item\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/info-communication\/reviews-reports-recommendations\/\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"Global genomic surveillance strategy for pathogens with pandemic and epidemic potential, 2022\u20132032\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#website\",\"url\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/\",\"name\":\"French\u00a0National ANTIBIOTIC RESISTANCE Portal\",\"description\":\"INSERM - From science to health\",\"publisher\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-GB\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#organization\",\"name\":\"Inserm\",\"url\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-GB\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2020\/05\/logo-inserm-ppra.svg\",\"contentUrl\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2020\/05\/logo-inserm-ppra.svg\",\"width\":1,\"height\":1,\"caption\":\"Inserm\"},\"image\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#\/schema\/person\/6ae79ca06cbeaec66ef5e976b54606b3\",\"name\":\"\u00c9milie Noguez\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Global genomic surveillance strategy for pathogens with pandemic and epidemic potential, 2022\u20132032 - French\u00a0National ANTIBIOTIC RESISTANCE Portal","description":"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l'Antibior\u00e9sistance en France et \u00e0 l'international.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/bilans-rapports-et-recommandations\/global-genomic-surveillance-strategy-for-pathogens-with-pandemic-and-epidemic-potential-2022-2032\/","og_locale":"en_GB","og_type":"article","og_title":"Global genomic surveillance strategy for pathogens with pandemic and epidemic potential, 2022\u20132032 - French\u00a0National ANTIBIOTIC RESISTANCE Portal","og_description":"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l'Antibior\u00e9sistance en France et \u00e0 l'international.","og_url":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/bilans-rapports-et-recommandations\/global-genomic-surveillance-strategy-for-pathogens-with-pandemic-and-epidemic-potential-2022-2032\/","og_site_name":"French\u00a0National ANTIBIOTIC RESISTANCE Portal","article_published_time":"2022-03-31T13:14:10+00:00","article_modified_time":"2022-03-31T13:14:12+00:00","og_image":[{"width":217,"height":299,"url":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2022\/03\/ADN.jpg","type":"image\/jpeg"}],"author":"\u00c9milie Noguez","twitter_card":"summary_large_image","twitter_misc":{"Written by":"\u00c9milie Noguez","Estimated reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"NewsArticle","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/bilans-rapports-et-recommandations\/global-genomic-surveillance-strategy-for-pathogens-with-pandemic-and-epidemic-potential-2022-2032\/#article","isPartOf":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/bilans-rapports-et-recommandations\/global-genomic-surveillance-strategy-for-pathogens-with-pandemic-and-epidemic-potential-2022-2032\/"},"author":{"name":"\u00c9milie Noguez","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#\/schema\/person\/6ae79ca06cbeaec66ef5e976b54606b3"},"headline":"Global genomic surveillance strategy for pathogens with pandemic and epidemic potential, 2022\u20132032","datePublished":"2022-03-31T13:14:10+00:00","dateModified":"2022-03-31T13:14:12+00:00","mainEntityOfPage":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/bilans-rapports-et-recommandations\/global-genomic-surveillance-strategy-for-pathogens-with-pandemic-and-epidemic-potential-2022-2032\/"},"wordCount":132,"publisher":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#organization"},"image":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/bilans-rapports-et-recommandations\/global-genomic-surveillance-strategy-for-pathogens-with-pandemic-and-epidemic-potential-2022-2032\/#primaryimage"},"thumbnailUrl":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2022\/03\/ADN.jpg","articleSection":["Actualit\u00e9s","Bilans, rapports et recommandations"],"inLanguage":"en-GB"},{"@type":["WebPage","ItemPage"],"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/bilans-rapports-et-recommandations\/global-genomic-surveillance-strategy-for-pathogens-with-pandemic-and-epidemic-potential-2022-2032\/","url":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/bilans-rapports-et-recommandations\/global-genomic-surveillance-strategy-for-pathogens-with-pandemic-and-epidemic-potential-2022-2032\/","name":"Global genomic surveillance strategy for pathogens with pandemic and epidemic potential, 2022\u20132032 - French\u00a0National ANTIBIOTIC RESISTANCE Portal","isPartOf":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/bilans-rapports-et-recommandations\/global-genomic-surveillance-strategy-for-pathogens-with-pandemic-and-epidemic-potential-2022-2032\/#primaryimage"},"image":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/bilans-rapports-et-recommandations\/global-genomic-surveillance-strategy-for-pathogens-with-pandemic-and-epidemic-potential-2022-2032\/#primaryimage"},"thumbnailUrl":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2022\/03\/ADN.jpg","datePublished":"2022-03-31T13:14:10+00:00","dateModified":"2022-03-31T13:14:12+00:00","description":"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l'Antibior\u00e9sistance en France et \u00e0 l'international.","breadcrumb":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/bilans-rapports-et-recommandations\/global-genomic-surveillance-strategy-for-pathogens-with-pandemic-and-epidemic-potential-2022-2032\/#breadcrumb"},"inLanguage":"en-GB","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/bilans-rapports-et-recommandations\/global-genomic-surveillance-strategy-for-pathogens-with-pandemic-and-epidemic-potential-2022-2032\/"]}]},{"@type":"ImageObject","inLanguage":"en-GB","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/bilans-rapports-et-recommandations\/global-genomic-surveillance-strategy-for-pathogens-with-pandemic-and-epidemic-potential-2022-2032\/#primaryimage","url":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2022\/03\/ADN.jpg","contentUrl":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2022\/03\/ADN.jpg","width":217,"height":299,"caption":"Cr\u00e9dit : Pixabay"},{"@type":"BreadcrumbList","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/bilans-rapports-et-recommandations\/global-genomic-surveillance-strategy-for-pathogens-with-pandemic-and-epidemic-potential-2022-2032\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/"},{"@type":"ListItem","position":2,"name":"Practical info & communications","item":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/info-communication\/"},{"@type":"ListItem","position":3,"name":"Reviews, reports and recommendations","item":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/info-communication\/reviews-reports-recommendations\/"},{"@type":"ListItem","position":4,"name":"Global genomic surveillance strategy for pathogens with pandemic and epidemic potential, 2022\u20132032"}]},{"@type":"WebSite","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#website","url":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/","name":"French\u00a0National ANTIBIOTIC RESISTANCE Portal","description":"INSERM - From science to health","publisher":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-GB"},{"@type":"Organization","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#organization","name":"Inserm","url":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-GB","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#\/schema\/logo\/image\/","url":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2020\/05\/logo-inserm-ppra.svg","contentUrl":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2020\/05\/logo-inserm-ppra.svg","width":1,"height":1,"caption":"Inserm"},"image":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#\/schema\/person\/6ae79ca06cbeaec66ef5e976b54606b3","name":"\u00c9milie Noguez"}]}},"publishpress_future_action":{"enabled":false,"date":"2026-04-14 17:51:05","action":"change-status","newStatus":"private","terms":[],"taxonomy":"category"},"post_mailing_queue_ids":[],"_links":{"self":[{"href":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/wp-json\/wp\/v2\/posts\/22733"}],"collection":[{"href":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/wp-json\/wp\/v2\/users\/139"}],"replies":[{"embeddable":true,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/wp-json\/wp\/v2\/comments?post=22733"}],"version-history":[{"count":9,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/wp-json\/wp\/v2\/posts\/22733\/revisions"}],"predecessor-version":[{"id":22755,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/wp-json\/wp\/v2\/posts\/22733\/revisions\/22755"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/wp-json\/wp\/v2\/media\/22741"}],"wp:attachment":[{"href":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/wp-json\/wp\/v2\/media?parent=22733"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/wp-json\/wp\/v2\/categories?post=22733"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/wp-json\/wp\/v2\/tags?post=22733"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}